RecruitingPhase 1NCT07630545

A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.

A Multi-part, Adaptive Phase 1, First Time in Human Study in Healthy Volunteers to Assess Safety, Tolerability and Pharmacokinetics (PK) Following Single Ascending Dose (SAD) and Multiple Ascending Doses (MAD) of MTX325, Including Option to Assess: a Single Dose in Elderly Participants; Multiple Doses in Patients With Parkinson's Disease (PD); Central Nervous System (CNS) Penetration, Biodistribution, and Biomarkers; and the Effect of Food on PK.

Sponsor

Mission Therapeutics

Enrollment

106 participants

Start Date

Nov 30, 2023

Study Type

INTERVENTIONAL

Conditions

Early-stage Parkinson’s disease Parkinson's Disease (PD)Mild to Moderate Parkinson's Disease

Summary

The goal of this study is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called MTX325 and Placebo for people with early-stage parkinson’s disease, mild to moderate parkinson's disease, and other related conditions. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.